Real-World study reveals how breast cancer drugs are actually used in portugal

NCT ID NCT07223476

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how CDK4/6 inhibitors are used in everyday practice for advanced breast cancer in Portugal. Researchers analyzed data from 16 public hospitals to understand dosing patterns, treatment duration, and how often doses were adjusted. The study included nearly 2,000 patients treated between 2018 and 2023.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib)
What this could lead to: If successful, this study could help doctors understand how these drugs are actually used in clinics, potentially leading to better dosing guidelines and improved patient care.
What could go wrong: This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Novartis

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.